Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (noted as Altery Therapeutics Ltd in metadata) covers the month of November 2010, with a specific reporting date of November 3, 2010. The registrant is an Australian entity (ACN: 080 699 065) headquartered in Parkville, Victoria. The filing serves to disclose changes in directors' relevant interests in securities and contracts pursuant to ASX Listing Rule 3.19A.2.
Key Financial Metrics
The filing text does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a regulatory disclosure regarding director shareholdings and option expiries.
Material Changes Versus Prior Period
The primary material change reported is the expiry of options held by five directors on October 31, 2010. No new securities were acquired or disposed of during this period; the changes reflect the reduction of option holdings to zero or adjusted totals due to expiration.
- Geoffrey Kempler: Options reduced from 2,000,000 to 0 (expiry of PBTAG Options). Total shares held: 17,055,000.
- George Mihaly: Options reduced from 650,000 to 0 (expiry of PBTAG Options). Total shares held: 226,666.
- Brian Meltzer: Options reduced from 650,000 to 0 (expiry of PBTAG Options). Total shares held: 326,666.
- Peter Marks: Options reduced from 650,000 to 0 (expiry of PBTAG Options). Total shares held: 43,111.
- Paul Marks: Options reduced from 701,754 to 350,877 (expiry of PBTAZ Options). Total shares held: 8,589,361.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary, or risk factors regarding the company's future operations or financial position. The only noted contingency is the administrative adjustment of holdings due to the scheduled expiry of specific option classes (PBTAG and PBTAZ).
Investor Verification Checklist
- Verify the current status of the PBTAG and PBTAZ option classes to confirm they have fully expired or been replaced.
- Confirm the total number of outstanding shares and options for the company to assess the dilution impact of the remaining options held by Paul Marks (350,877).
- Review the company's most recent Form 20-F or annual report for actual financial performance metrics, as this 6-K contains none.
- Check for any subsequent filings regarding the "CFO Solution" contract mentioned in Part 2 of the notices, as no specific details were provided in this text.